{"url":"https://lda.senate.gov/api/v1/filings/c19ebd7a-203f-4a56-aab0-8b794c28ca5a/","filing_uuid":"c19ebd7a-203f-4a56-aab0-8b794c28ca5a","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2022,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c19ebd7a-203f-4a56-aab0-8b794c28ca5a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Patricia Knight","dt_posted":"2022-10-17T17:55:53-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1701 Pennsylvania Avenue, NW","registrant_address_2":"Suite 900","registrant_different_address":false,"registrant_city":"Washington,","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":40036301,"url":"https://lda.senate.gov/api/v1/registrants/40036301/","house_registrant_id":39935,"name":"KNIGHT CAPITOL CONSULTANTS","description":"Government Relations","address_1":"817 North Lincoln Street","address_2":null,"address_3":null,"address_4":null,"city":"Arlington","state":"VA","state_display":"Virginia","zip":"22201","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PATRICIA KNIGHT","contact_telephone":"+1 202-510-5264","dt_updated":"2026-04-04T22:55:29.375651-04:00"},"client":{"id":210713,"url":"https://lda.senate.gov/api/v1/clients/210713/","client_id":125,"name":"REGENXBIO","general_description":"Develop innovative therapies to treat patients with rare or otherwise debilitating disease","client_government_entity":false,"client_self_select":null,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-05-03"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Potential legislation implementing value based purchasing for pharmaceuticals (HR 7389); Possible provisions related to Drug Pricing Legislation that affect biological products' development, approval, accelerated approval, and marketing, including deliberations associated with the Reauthorization of the Prescription Drug User Fee Act ( HR 7667) (S 4348), or the continuing resolution(Further Extendjnf Government Funding Act P.L. 117-70. Possible drug pricing legislation included in any budget reconciliation legislation ( no specific number). Reauthorization of the Newborn Screening Saves Lives Act (HR 482, S 350.)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":40329,"prefix":null,"prefix_display":null,"first_name":"PATRICIA","nickname":null,"middle_name":null,"last_name":"KNIGHT","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":40329,"prefix":null,"prefix_display":null,"first_name":"PATRICIA","nickname":null,"middle_name":null,"last_name":"KNIGHT","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":40329,"prefix":null,"prefix_display":null,"first_name":"PATRICIA","nickname":null,"middle_name":null,"last_name":"KNIGHT","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch","new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Potential changes in the corporate tax rate or other provisions of interest to business (Build Back Better Act, H.R. 5376 or any successor budget reconciliation legislation).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":40329,"prefix":null,"prefix_display":null,"first_name":"PATRICIA","nickname":null,"middle_name":null,"last_name":"KNIGHT","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch.","new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}